Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial-Reference-Cited by-同舟云学术

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Published:2012-10 Issue:4 Volume:57 Page:821-829
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Bruix Jordi,Raoul Jean-Luc,Sherman Morris,Mazzaferro Vincenzo,Bolondi Luigi,Craxi Antonio,Galle Peter R.,Santoro Armando,Beaugrand Michel,Sangiovanni Angelo,Porta Camillo,Gerken Guido,Marrero Jorge A.,Nadel Andrea,Shan Michael,Moscovici Marius,Voliotis Dimitris,Llovet Josep M.

Publisher

Elsevier BV

Subject

Hepatology

Reference42 articles.

1. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma;Llovet;J Natl Cancer Inst,2008

2. Hepatocellular carcinoma;Forner;Lancet,2012

3. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

4. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy;Imamura;J Hepatol,2003

5. Novel advancements in the management of hepatocellular carcinoma in 2008;Llovet;J Hepatol,2008

Cited by 725 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10

2. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

3. The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion;Cancers;2024-07-14

4. Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma–Authors' reply;Hepatology Research;2024-06-29

5. Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis;European Journal of Clinical Pharmacology;2024-06-22